The current ongoing clinical trials with the second generation of Tau PET tracers have great potential to provide high specific signals and therefore will facilitate diagnosis of tau-related neurodegenerative diseases (reported in Section 4). This evidence concerns the gene MAPT and neurodegenerative disease.